DIPG Brain Tumors

DIPG Brain Tumors are rare, aggressive tumors in the brainstem. They form in the glial cells of the pons. These tumors are very difficult to treat and often grow quickly, leading to severe symptoms like difficulty breathing and swallowing.

Condition

What people with DIPG Brain Tumors report

Every report comes from a Lived member, sent anonymously.

Have you tried Radiation Therapy for DIPG Brain Tumors?

NameHow it went

About DIPG Brain Tumors

What It Is

Diffuse intrinsic pontine glioma (DIPG) is a fast-growing brain tumor that starts in the pons, part of the brain stem just above the back of the neck. The pons helps control breathing, heart rate and blood pressure, and it carries the nerves that move the eyes and face and allow talking, chewing, swallowing and walking. Because the tumor grows within this tissue rather than as a separate lump, it disrupts those functions early and is especially hard to treat. DIPG is a type of glioma, a tumor that arises from glial cells, which support and protect nerve cells. It mainly affects children between about 5 and 10 years old, can occur in younger children and teenagers, and is rare in adults. In the United States, about 300 children are diagnosed each year. Under the microscope, most of these tumors are what pathologists now call diffuse midline glioma, H3 K27-altered, a grade 4 (the most aggressive grade) tumor that can also arise in the thalamus or spinal cord. DIPG is different from focal brain stem tumors, which are confined to one spot, can often be removed and have a far better outlook.

Causes & Risk Factors

DIPG develops when glial cells acquire changes that make them grow and divide abnormally. In most cases the tumor cells carry a change in a histone gene (the H3 K27M change), which alters how many other genes are switched on and off. This change is a feature of the tumor itself and helps define it, but why it arises in a particular child is not known. There are no known risk factors for DIPG. No exposure, diet, illness or parenting choice has been shown to cause it, and there is no screening test that can detect it early.

How It's Diagnosed

Symptoms usually appear quickly. Common early signs include an eye that turns inward or trouble moving the eyes, double vision, drooping on one side of the face, slurred speech or trouble swallowing, weakness in the arms or legs, and clumsiness or a new unsteady walk. Some children have morning headaches or vomiting, or changes in behavior or schoolwork. A doctor takes a history and does a neurological exam that checks eye movements, facial strength, balance and coordination. Magnetic resonance imaging (MRI) of the brain is the key test. DIPG has a characteristic appearance: a tumor that swells and spreads through the pons rather than sitting beside it. When the symptoms and MRI fit the classic pattern, specialists have often made the diagnosis without taking tissue. A biopsy, in which a neurosurgeon removes a small sample with a needle guided by imaging, is increasingly done. It confirms the tumor type, identifies genetic changes such as H3 K27M that can affect prognosis and eligibility for clinical trials, and is recommended when the MRI does not clearly show DIPG. Because the pons is so delicate, biopsy carries a risk of new neurological problems and is best done by an experienced pediatric neurosurgeon. Families can ask for a second opinion on the scans or pathology before treatment starts.

Treatment Options

DIPG cannot be removed with surgery, because the tumor is woven through brain stem tissue that controls vital functions. Radiation therapy to the tumor is the standard first treatment for children. It is usually given as daily treatments over several weeks. Most children feel better for a time, with improvement in walking, speech or eye movements, but the benefit is temporary. A shorter course using fewer, larger doses gives similar survival and may lighten the treatment burden. Infants are usually given chemotherapy instead of radiation, because radiation can affect a very young child's developing brain. Chemotherapy and other drugs added to radiation have not been shown to help children with DIPG live longer. Dordaviprone (Modeyso), a capsule taken by mouth, received accelerated approval from the US Food and Drug Administration (FDA) in 2025 for people aged 1 and older with diffuse midline glioma carrying the H3 K27M change that has grown after earlier treatment. That approval rested on tumor shrinkage in about 1 in 5 mostly adult patients whose tumors were outside the pons, and people with DIPG were excluded from those studies, so its benefit for DIPG has not been established. It also requires heart rhythm monitoring. If the tumor grows again after an initial good response, a second course of radiation can relieve symptoms and may extend survival for some children. Fluid can build up in the brain when the tumor blocks its normal drainage (hydrocephalus); a shunt, a thin tube that drains fluid to the abdomen, or a similar procedure can relieve the pressure. Because standard treatment does not cure DIPG, clinical trials of new drugs, immune therapies and delivery methods are an important option, and some trials enroll only children who have not yet started treatment. Palliative care, which focuses on comfort, symptom relief and support for the whole family, belongs alongside treatment from the time of diagnosis, not only at the end.

What to Expect

DIPG is one of the most serious childhood cancers. There is currently no cure, and most children do not live longer than 2 years after diagnosis; the median survival is less than a year. About 1 in 10 children live beyond 2 years. Outlook varies with age and tumor features: very young children and those whose symptoms developed slowly tend to do somewhat better. The course often follows a recognizable pattern. Symptoms usually ease during or after radiation, and many children have a stretch of time when they feel and function better. Follow-up MRI scans track the tumor. Scans a few months after radiation can show changes caused by the treatment itself that look like growth, so care teams confirm true progression before changing course. When the tumor grows again, earlier symptoms tend to return and progress, often with more difficulty swallowing, speaking and moving. Daily life is shaped by these changes and by treatment visits. As the tumor progresses, children may need more help with eating, moving and communicating. A team that can include a pediatric oncologist, radiation oncologist, neurosurgeon, palliative care specialists, therapists, psychologists, social workers and child-life specialists helps the child and family. Siblings and parents also need support, and planning early for what matters most to the child and family allows care to follow those wishes as needs change.

When to Seek Help

A child who develops eye movement problems, double vision, facial drooping, slurred speech, trouble swallowing, new weakness or unsteady walking, especially if they appear together or worsen quickly, should be checked by a doctor right away. These signs have other causes, but they need prompt evaluation and often brain imaging. For a child already diagnosed, contact the care team promptly about worsening headaches, repeated vomiting, unusual sleepiness, irritability or a seizure, which can mean rising pressure from fluid buildup, as well as about choking or coughing with meals or any rapid change in abilities. The palliative care team can also help manage distressing symptoms as they arise.

Questions to Ask Your Doctor

  1. 1.Does the MRI clearly show DIPG, and would a biopsy change my child's treatment or open up clinical trials?
  2. 2.What can radiation realistically do for my child, and how will we know if it is working?
  3. 3.Which clinical trials is my child eligible for, and do any require enrolling before treatment begins?
  4. 4.What changes should we watch for at home, and who do we call at night or on weekends?
  5. 5.How can palliative care, counseling and other support help our child and family now?

Last reviewed • Oct 2026

Educational content, not medical advice.